Tyra Biosciences (NASDAQ:TYRA) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Tyra Biosciences (NASDAQ:TYRA) issued its quarterly earnings results on Tuesday. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07), FiscalAI reports.

Tyra Biosciences Stock Down 2.7%

Tyra Biosciences stock traded down $0.60 during midday trading on Tuesday, reaching $21.70. The company’s stock had a trading volume of 105,705 shares, compared to its average volume of 889,703. Tyra Biosciences has a fifty-two week low of $13.83 and a fifty-two week high of $40.65. The company has a market cap of $1.30 billion, a P/E ratio of -9.05 and a beta of 0.65. The business has a 50-day simple moving average of $22.12 and a 200-day simple moving average of $29.59.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TYRA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a research report on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Thursday, October 15th. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective (down from $50.00) on shares of Tyra Biosciences in a research note on Tuesday, September 22nd. Jefferies Financial Group restated a “buy” rating and issued a $42.00 price objective on shares of Tyra Biosciences in a report on Wednesday, August 5th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $50.00 target price on shares of Tyra Biosciences in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.20.

About Tyra Biosciences

Tyra Biosciences, Inc is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges.

The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.